Kura Oncology, Inc.
KURA
$8.58
-$0.15-1.72%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -67.83% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -67.83% | -- | -- | -- | -- |
| Cost of Revenue | 23.34% | 62.83% | 58.04% | 54.33% | -54.64% |
| Gross Profit | -3,016.40% | -13.08% | -19.56% | -15.43% | 101.40% |
| SG&A Expenses | 62.60% | 80.64% | 50.92% | 25.58% | 69.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.72% | 68.24% | 55.94% | 44.73% | 63.25% |
| Operating Income | -284.18% | -33.59% | -28.83% | -18.82% | 51.98% |
| Income Before Tax | -370.54% | -36.23% | -30.07% | -15.50% | 59.80% |
| Income Tax Expenses | -96.48% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -321.50% | -36.23% | -30.07% | -15.96% | 55.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -321.50% | -36.23% | -30.07% | -15.96% | 55.09% |
| EBIT | -284.18% | -33.59% | -28.83% | -18.82% | 51.98% |
| EBITDA | -285.89% | -33.78% | -28.90% | -18.89% | 52.20% |
| EPS Basic | -317.19% | -35.14% | -28.65% | -11.30% | 60.14% |
| Normalized Basic EPS | -191.68% | -35.13% | -28.66% | -10.87% | 48.42% |
| EPS Diluted | -317.19% | -35.14% | -28.65% | -11.30% | 60.14% |
| Normalized Diluted EPS | -191.68% | -35.13% | -28.66% | -10.87% | 48.42% |
| Average Basic Shares Outstanding | 1.05% | 0.80% | 1.10% | 4.18% | 12.67% |
| Average Diluted Shares Outstanding | 1.05% | 0.80% | 1.10% | 4.18% | 12.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |